Status:
COMPLETED
A Study of Infliximab in Patients With Sarcoidosis
Lead Sponsor:
Centocor, Inc.
Conditions:
Sarcoidosis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis. Infliximab (Remicade) targets specific proteins in the body's immun...
Detailed Description
The purpose of this study is to evaluate the safety and effectiveness of infliximab in the treatment of subjects with sarcoidosis with pulmonary involvement who show symptoms of the disease even thoug...
Eligibility Criteria
Inclusion
- Patients must have been diagnosed with sarcoidosis at least 1 year prior to entry into the study
- Patients must have laboratory test diagnosing sarcoidosis prior to screening
- Patients must have a diagnosis of sarcoidosis by chest x- ray
Exclusion
- Patients must not have used any investigational drug within 1 month prior to entering the study
- Patients must not have received previous administration of a treatment with any other therapeutic agent targeted at reducing TNF such as pentoxifylline, thalidomide, etanercept, CDP 870, adalimumab, within 3 months prior to screening
- Patients must not have received vaccinations within 3 months
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT00073437
Start Date
October 1 2003
End Date
February 1 2005
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.